Trials / No Longer Available
No Longer AvailableNCT02960620
Therasphere for Unresectable Primary or Secondary Liver Neoplasia
A Humanitarian Device Exemption (HDE) Treatment Protocol of TheraSphere® For Treatment of Unresectable Primary or Secondary Liver Neoplasia - HDE #980006
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This is not a research study. The purpose is to provide supervised access to TheraSphere® therapy at this institution.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | TheraSphere Treatment | TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. The hepatic artery provides the main blood supply to the tumor in the liver, whereas the portal vein supplies blood to normal liver parenchyma. TheraSphere® is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with relatively limited concurrent injury to surrounding normal tissue. |
Timeline
- First posted
- 2016-11-09
- Last updated
- 2022-09-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02960620. Inclusion in this directory is not an endorsement.